Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma 14Ovarian Neoplasms 6Neoplasms 5Liposarcoma 5Leiomyosarcoma 5Liposarcoma, Myxoid 3Breast Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neoplasms by Site 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Ichthyosis, X-Linked 2Endometrial Neoplasms 2Uterine Neoplasms 1Solitary Fibrous Tumors 1Soft Tissue Neoplasms 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Recurrent High Grade Meningioma 1Pancreatic Neoplasms 1Ovarian Diseases 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Malignant mesenchymal tumor 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Trabectedin × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00580112 2014-02-25

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
127 enrolled
Breast

Breast Neoplasms

NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡